Oral Glucokinase Activator Gets Breakthrough Tx Status for Type 1 Diabetes
TTP399 is an investigational oral, hepatoselective glucokinase activator.
Endocrine Disorders
Trial Evaluating Dapagliflozin in Hospitalized COVID-19 Patients Misses Endpoints
The DARE-19 trial evaluated dapagliflozin in addition to standard of care in reducing disease progression, clinical complications and all-cause mortality in 1250 adults hospitalized with COVID-19.
Ozempic Injection 1mg Now Available as a Single Monthly Pen
Anavip contains venom-specific F(ab’)2 fragments of immunoglobulin G that bind and neutralize venom toxins.
More Tepezza Will Be Available Starting in April
Tepezza, a fully human monoclonal antibody, is approved for the treatment of thyroid eye disease.
Zegalogue Approved for Severe Hypoglycemia in Patients With Diabetes
Zegalogue is a glucagon analogue that is formulated in a ready-to-use aqueous solution for subcutaneous administration.
Common Meds Interfere With TFTs in Older Adults on Thyroid Hormone
Almost one-third of older adults on thyroid replacement therapy take at least one medication that interferes with thyroid function tests
USPSTF Urges Prediabetes, T2DM Screen for Overweight Adults
Physicians should screen overweight, obese adults aged 35 to 70 years and refer those with prediabetes to preventive interventions
Pancreatic Islet Replacement Therapy Fast Tracked for Type 1 Diabetes
VX-880 is an investigational allogeneic human stem cell-derived islet cell therapy that may restore pancreatic islet cell function.
Semaglutide May Aid Weight Loss in Obese Patients With T2DM
Estimated change in mean body weight to week 68 was −9.6 percent with semaglutide 2.4 mg versus −3.4 percent with placebo
Tirzepatide Superior to Semaglutide in Head-to-Head Type 2 Diabetes Study
Tirzepatide is a novel, once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that integrates the actions of both incretins into a single molecule.
